Coenzyme Q10 and Vitamin A Composition for Vocal Cord Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vocal and olfactory disorders, such as vocal cord nodules and olfactory dysfunctions, are limited in effectiveness and do not provide comprehensive relief, particularly in cases of vocal abuse and misuse leading to chronic inflammatory processes and changes in muscular dynamics.
Innovation Solution
A composition comprising coenzyme Q10 and vitamin A, combined with pharmaceutically acceptable excipients, is used to treat phonatory and olfactory apparatus disorders, enhancing energy production, antioxidant activity, and tissue protection, thereby addressing the underlying causes of vocal fatigue and olfactory dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If logopaedic therapy and vitamin A alone are used to treat vocal cord disorders, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent combines coenzyme Q10 and vitamin A into a single pharmaceutical composition for treating vocal cord disorders. This merging of two active ingredients with complementary mechanisms (coenzyme Q10 for energy metabolism and antioxidant protection, vitamin A for epithelial repair and anti-inflammatory effects) resolves the contradiction by enhancing therapeutic effectiveness while maintaining treatment simplicity through a unified formulation.
Solution Approach 2:
The invention creates a composite pharmaceutical material combining coenzyme Q10 and vitamin A in specific proportions (coenzyme Q10: 1-50 mg per dose, vitamin A: 0.1-10 mg per dose). This composite approach leverages the synergistic effects of both components, addressing the insufficient effectiveness of single-agent therapies while providing a ready-to-use composite product that doesn't increase complexity for the end user.
2Reliability
If coenzyme Q10 and vitamin A are combined in a composition, then therapeutic effectiveness is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent specifies optimized dosage ranges for coenzyme Q10 (1-50 mg) and vitamin A (0.1-10 mg) per dose, along with their weight percentage ranges in the composition. These parameter definitions provide clear manufacturing targets and quality control criteria, resolving the contradiction by enabling enhanced therapeutic effectiveness through proven effective dosages while simplifying manufacturing through well-defined parameter specifications.
3Reliability
If individual treatments are used separately, then treatment protocol simplicity is maintained, but synergistic therapeutic effects are not achieved
Solution Approach 1:
The patent merges coenzyme Q10 and vitamin A into a single pharmaceutical composition, delivering synergistic therapeutic effects for vocal cord disorders. This resolves the contradiction by combining two treatments that work through different mechanisms (energy metabolism/antioxidant vs. epithelial repair/anti-inflammatory) into one unified product, achieving synergistic effects without requiring patients to manage multiple separate treatments.
Data Source
Figure 1
Figure 2
AI summary
A composition is described consisting of coenzyme Q10, vitamin A and suitable excipients for treating phonatory and olfactory apparatus disorders, such as anosmia and dysosmia.